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Abstract

Chronic pain has become a public health epidemic. As pain complaints increase, so does
the potential for drug abuse/misuse. Prescription drug monitoring programs (PDMPs) are active
in 49 of the 50 states to assist providers in recognizing drug abuse/misuse. There is no clear
standardization of who utilizes the PDMP and how. Little is still known about the ways PDMP
results are incorporated into clinical decision making, what barriers exist, and how providers
may or may not alter their prescribing plans based on the results. Laws surrounding prescribing
practices and use of the Ohio Automated Rx Reporting System (OARRS) are constantly updated.
Existing literature was reviewed regarding state PDMPs, OARRS, Ohio Revised Code,
limitations of PDMPs, and physician assistants (PAs) role in using the OARRS. Current
literature shows underutilization and lack of awareness of the OARRS by PAs. Quantitative data
was collected using a twenty-six question electronic survey distributed to PAs actively licensed
to practice in the State of Ohio as of February 25, 2014 (n= 2563) with a rate of return of 15.6%.
Results showed 73.80% of PAs indicated that they were currently enrolled in OARRS and
26.20% indicated they were not enrolled. Of the PAs enrolled in OARRS, 71.87% responded that
they do utilize the OARRS and of those enrolled, 74.04% report an average use of at least once
per week. Routines for enrolling, accessing, and responding to OARRS results vary widely. As
iii

controlled substance prescribing and use of OARRS increases, it is important to understand what
approaches are most effective for identifying and addressing enrollment and utilization of the
OARRS. Future trends for OARRS education on increasing enrollment and utilization of
OARRS are described.

Keywords: OARRS, Prescription drug monitoring program, Physician assistant
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CHAPTER 1
Physician assistants (PAs) with prescriptive privileges allow for a cost effective and
efficient bridge of the medical care gap. PAs provide increased access to desperately needed
medical care (Cipher, Hooker, & Guerra, 2006). Hooker, Cawley and Everett (2011) agree that
PAs have been essential during times of physician shortages. The number of board certified and
licensed PAs continues to grow each year (Hooker et al., 2011; NP/PA prescribing stats, 2006;
and Ross, Parle, Begg, & Kuhns, 2012). As the PA profession expands so does the need to write
prescriptions for scheduled medications. The ability to prescribe scheduled medications is
imperative to best practice medicine. Best practice medicine includes prevention, identification,
and treatment of illnesses.
As the need and ability for PAs to write prescriptions increases, so does the need to do so
safely and responsibly. Rules, regulations and laws regarding a PA’s prescribing ability are still
in their infancy and vary widely by state and institution. White and Davis (1999) found that
“very early in the PA profession it became apparent to supervising physicians that their practice
could be more efficient if they were allowed to delegate to PAs the prescription of medications”
(p. 958). PAs have been prescribing medications since the 1980s when legislation was passed
that allowed prescriptive privileges for PAs in several states (Physician Assistant Historical
Society, 2013). According to the Drug Enforcement Administration (2013) and the American
Academy of Physician Assistants (2010), currently 48 of the 50 states and the District of
Columbia allow PAs the privilege to prescribe scheduled medications. PAs are often called upon
to treat patients who have pain and require scheduled medications including opioid analgesics.

“Approximately 75 million people in the United States suffer from severe pain, which is the most
common presenting complaint of patients seeking medical assistance” (Brushwood, 2003, p. 41).
The ability to prescribe scheduled medications carries with it a duty to prescribe safely and
responsibly.
Pain can be treated in different ways. Pain can be treated non-pharmacologically with
interventions such as anesthesia assistance, behavioral counseling, nerve stimulation, physical
therapy, acupuncture, or massage. Pain can also be treated with medications such as nonsteroidal anti-inflammatory medications, anti-depressants, or opioid analgesics. When
medications become the treatment of choice for pain (regardless of the origin of the pain) a
balance must be achieved between safe and effective pain management and substance abuse.
In 2006 the State of Ohio passed Senate Bill 154 giving physician assistants the right to
prescribe schedule III-V medications (Bricker & Eckler LLP, 2006; S.B. 154, 2006).
“Supervised prescribing (by PAs), as regulated by the state and by the physician supervisor, can
improve patient access to comprehensive care and provide for increased efficiency and cost
effectiveness” (Younger, P. A., & Aspen Health Law Center, 1997, p. 100). Some scheduled
medications required prescriptions written by an attending physician with limited availability
thus delaying relief for severe pain. In March 2013 House Bill 284 passed giving Ohio PAs
prescriptive privileges of schedule II medications.
As an added security resource, the Ohio Automated Rx Reporting System (OARRS)
program was established in 2006. The OARRS is a state-wide prescription drug monitoring
program. OARRS is available, via registration through a secure website, to all prescribers, law
enforcement officers, and pharmacists. With the addition of Schedule II medications to PAs’
prescribing rights many Ohio employers found it necessary to establish or revise existing policy
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for PA prescribing. During the policy analysis at one Ohio medical center, concerns about the
safety of prescribing scheduled medications were identified.
The purpose of the OARRS program is to “improve patient care and identify drug
seeking behavior” (Feldman, Skeel-Williams, Knox, & Coates, 2012, p. 909) by tracking every
prescription written for scheduled (II-V) medications. OARRS is designed to decrease abuse,
misuse, “doctor shopping” (obtaining controlled substances from multiple health care providers
without the prescribers’ knowledge of the other prescriptions) and polypharmacy, which is the
use of multiple medications concurrently (Blumenschein et al. 2010; Feldman et al., 2011; Ohio
Academy of Family Physicians, 2012).
Multiple evaluations of state prescription monitoring programs have been undertaken in
several medical fields but have not resulted in the development of a standard protocol for
awareness and utilization of state prescription monitoring programs. Analysis of awareness and
utilization of state prescription monitoring programs has been explored in fields including
emergency medicine, pharmacy, pain management, psychology, and physician utilization
(Baehren et al., 2010; Barrett & Watson, 2005; Clark, 1991; Feldman et al., 2012; Gilson &
Joranson, 2001; Joranson et al., 2002; Katz et al., 2008; Todd, 2010; Ulbrich, Dula, Green,
Porter, & Bennett, 2010; Wang & Christo, 2009). To date, the awareness and utilization of the
OARRS by PAs has not been evaluated and thus it is unclear how effectively PAs access this
established system. Information on awareness and utilization of state prescription monitoring
programs by PAs may identify an influence on the prescribing of controlled substances.
Information collected could be used to help shape future policy regarding PAs’ prescriptive
privileges, education on PA prescribing in Ohio, and allow for safer and more effective
healthcare. Therefore, further research is needed to examine the awareness and utilization of the
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Ohio Automated Rx Reporting System by PAs.
Purpose of the Study
The purpose of this study is to examine the awareness and utilization of the Ohio
Automated Rx Reporting System by physician assistants.
Statement of the Problem
Physician assistants do not adequately utilize the Ohio Automated Rx Reporting System.
There is an overarching problem with prescription drug monitoring programs in that there is a
lack of unification. There is not one governing body; many but not all states have a prescription
drug monitoring program; there is no standardization of what information is collected, by whom,
or who may access it; there is no unified system of communication between the programs in each
state. However this larger problem is outside the scope of this study. The proposed study will
focus on specific population and specific state monitoring program. The results from this study
could be used to create local (hospital wide) and state policies regarding access and utilization of
the OARRS program.
Hypotheses
The following null hypotheses were based on the selected review of literature and the
intuition of the researcher:
1. Physician assistants actively licensed to practice in the State of Ohio are
unaware of the OARRS.
2. Physician assistants actively licensed to practice in the State of Ohio do not
utilize the OARRS.
3. No factors are predictive of awareness of OARRS by physician assistants
actively licensed to practice in the State of Ohio.
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4. No factors are predictive of utilization of OARRS by Physician assistants
actively licensed to practice in the State of Ohio.
5. Physician assistants actively licensed to practice in the State of Ohio do not
alter their prescribing plans as a result of utilization of OARRS.
Definition of Terms
For the purpose of this study, the following terms are defined.
Awareness: Knowing that something (such as a situation, condition, or problem) exists
(awareness, 2013).
Continuing medical education (CME): Includes but is not limited to: graduate education,
education for health professionals that follows completion of formal post-medical school
specialty training. Formats include but are not limited to: lectures, seminars, refresher
courses, workshops, audio- and video-recordings, professional organizations, hospitals
(continuing medical education, 2002)
Controlled substance: any drug defined in the five categories of the federal Controlled Substance
Act of 1970. The categories, or schedules, cover opium and its derivatives, hallucinogens,
depressants, and stimulants. Schedule I drugs have a high abuse potential and no
approved medical uses. Drugs in Schedules II to V all have approved medical indications
with decreasing abuse and dependence liabilities as the schedule number increases
(controlled substance, 2009).
Doctor shopping: Obtaining controlled substances from multiple health care providers without
the prescribers’ knowledge of the other prescriptions (Blumenschein, et al., 2010).
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Drug abuse/misuse: The use of a controlled substance in a maladaptive pattern resulting in
significant impairment or distress, such as failure to fulfill social or occupational
obligations or recurrent use in situations in which it is physically dangerous to do so or
which end in legal problems. Abuse also encompasses inappropriate use of medications
other than the explicit prescriber’s instructions (substance abuse, 2003).
Drug diversion: The channeling of controlled substances to another person(s) or for any use
other than prescribed by the provider. This can include: theft, forging, tampering,
counterfeiting, and illegal sales (Kasprak, J., 2003).
Drug Enforcement Administration (DEA): A United States Federal law enforcement agency
under the Department of Justice tasked with monitoring, controlling and preventing
illegal or inappropriate drug use (Drug Enforcement Agency; Office of Diversion
Control, 2013).
Medical provider: Doctor (M.D. or D.O.), dentist, nurse practitioner, physician assistant, or any
other healthcare provider who might prescribe medications. (Blumenschein et al., 2010).
OARRS: Ohio Automated Rx (Prescription) Reporting System.
Opioid analgesic: Medication that binds with the opioid receptors in the central nervous system
to block the perception of pain or affect the emotional response to pain (Opioid
Analgesic, 2007).
Physician assistant: A graduate of an accredited educational program and is nationally certified
and state-licensed to practice medicine with the supervision of a physician. PAs perform
physical examinations, diagnose and treat illnesses, order and interpret lab tests, perform
procedures, assist in surgery, provide patient education and counseling, and make rounds
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in hospitals and nursing homes. All 50 states and the District of Columbia allow PAs to
practice and prescribe medications (American Academy of Physician Assistants, 2013).
Polypharmacy: The use of multiple medications concurrently (Blumenschein et al., 2010).
Prescribing privileges: A legal privilege that must be applied for by the physician assistants in
their respective state that enables them to prescribe drugs and other medicines required
for the treatment of medical conditions (Brian, n.d.).
Prescription drug monitoring program: According to the National Alliance for Model State Drug
Laws (NAMSDL, 2013), a PDMP is a statewide electronic database that collects
designated data on substances dispensed in the state. The data from the database is
disseminated to individuals who are authorized under state law to receive the information
for purposes of their profession.
Scheduled medication: Substances are placed in their respective schedules based on whether they
have a currently accepted medical use in treatment in the United States, their relative
abuse potential, and the likelihood of causing dependence when abused. See Table 1.
(Drug Enforcement Agency; Office of Diversion Control, 2013).
Supervising physician: An allopathic or osteopathic physician (M.D. or D.O.) licensed to practice
in the state, which accepts responsibility for the supervision of services provided by a
physician assistant. Direction of the medical practice of the physician assistant is
provided and assured by a supervising physician, but this does not necessarily require the
physical presence of a supervising physician at the place where services are rendered
(American Academy of Physician Assistants, 2013).
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Treatment plan: The intended sequence of procedures for the treatment of a patient (treatment
plan, 2008).
Utilization: To make use of (Utilization, 2013).
Limitations of the Study
1) The study is limited to the physician assistants actively licensed to practice in the
State of Ohio. Therefore, findings from this study cannot be generalized to all
physician assistants or physician assistants in other states.
2) The study is limited to physician assistants. Therefore this study does not represent all
medical providers in the State of Ohio.
3) The completion of the survey is voluntary. Therefore some physician assistants may
choose not to complete the questionnaire, thus, limiting sample size.
4) The responses are self-reported.
Assumptions
The following were the basic assumptions of the design:
1. The questionnaire respondents’ interpretation of the questions is accurate.
2. The questionnaire respondents answer in an honest and thoughtful manner.
3. An existing research tool developed by Ulbrich et al. (2010) is used with permission and
adapted for physician assistants.
4. The questionnaire was previously tested for validity by Ulbrich et al. (2010).
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CHAPTER 2
LITERATURE REVIEW
The purpose of the chapter is to present a selected review of literature
related to the objectives of this study. The information provided is discussed employing the best
practice conceptual framework. The first section provides an outline of the best practice
conceptual framework as it pertains to the awareness and utilization of the Ohio Automated Rx
Reporting System by PAs. The second section of the review of literature discusses the history of
prescription drug monitoring programs. Identified negatives and limitations of prescription drug
monitoring programs are discussed in the third section. The fourth section presents information
about the Ohio Automated Rx Reporting System. The Ohio revised code is discussed in the fifth
section. The use of prescription drug monitoring program utilization in selected fields is
discussed in the sixth section. The seventh section discusses the PA’s role in prescription drug
monitoring programs. In the eighth section, PA pharmacologic education is discussed. The
chapter concludes with a summary of the selected review of literature.
Conceptual Framework
The conceptual framework used to examine the awareness and utilization of the Ohio
Automated Rx Reporting System by PAs is Solberg’s (2007) improving medical practice.
Improving medical practice is a framework that incorporates the vision for the PA profession;
“PAs transforming health through patient-centered, team-based medical practice – with its
hallmark of patient-centered, team-based care—as a driving force for significant improvement”
(American Academy of Physician Assistants, 2013, p. 7) Through this framework the
investigator
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attempts to quantify the awareness and utilization of the Ohio Automated Rx Reporting System
by PAs and how it could relate to future policies and optimal patient care.
The issue of appropriate use of opioids in the treatment of pain is complex and
controversial. This debate is often highlighted in improving medical practice discussions.
Feinberg (2011) relates that:
On one side there is the ever increasing problem of deaths and dysfunction from the
inappropriate use of opioids, and on the other side are the needs of patients for adequate
pain control to facilitate comfort, activity and function. For the provider and patient,
achieving a balance across the continuum of outcomes from pain relief, side effects,
addiction, abuse, diversion and potential death, remains problematic. (p. 1)
In response to the increasing morbidity and mortality associated with the increasing use
of opioids, the Centers for Disease Control and Prevention (2010) has released several
recommendations for health care providers for improving medical practice guidelines. The
Center for Disease Control and Prevention (2010) recommendations include:
The belief that opioid medications for pain should only take place after a determination
has been made that alternative therapies have not provided adequate pain relief.
Additionally, the lowest effective dose of opioids should be used. Behavioral screening,
patient agreements, and random urine testing should be strongly considered in patients
with pain, who have been treated with opioids for more than six weeks. (p. 4)
The improving medical practice framework dictates that “opioids (despite their potential
for problems) have a place in the practitioner’s treatment armamentarium when other methods
have failed and when the use of opioids results in less pain, more function and manageable sideeffects” (Feinberg, 2011, p. 3). Providers must examine opioid prescribing with a risk vs. benefit
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lens. If other non-opioid treatment methods fail and there is clinical indication for the use of
opioids, the provider may decide opioid therapy is appropriate.
History of Prescription Drug Monitoring Programs
Brushwood (2003) indicates that despite the availability of safe and effective pain
treatment options, many patients are either over or under treated. Every year thousands of visits
are made to medical offices, emergency rooms, and urgent care facilities for pain related
complaints. PAs are used to increase access to medical services. Due to increased availability, a
patient often sees a PA for his/her medical care. As PAs are seeing an increased number of
patients, and many of those patients with pain related complaints, the potential for writing
prescriptions for opioid medications increases. There is a need to utilize available safety
mechanisms and resources to prevent drug diversion and abuse.
There is no standard or measurement available for medical providers to determine if a
patient’s pain is legitimate or falsified. Medical providers rely on the patient’s history, physical
exam, and diagnostic tests to evaluate the need for opioid analgesics to treat pain. In order to
collect evidence on the problem of inappropriate prescribing and dispensing of controlled
substance medications and to facilitate a resolution to the problem, states began using
prescription drug monitoring programs (Brushwood, 2003; Fishman, Papazian, Gonzalez,
Riches, & Gilson, 2004; GAO-04-524T, 2004; Wilsey et al., 2011).
As medications for the management of pain have advanced over centuries, laws designed
to regulate access to such medications also developed. “Since the early 1930s, state regulatory,
administrative, and law enforcement agencies have seen the need for and have worked to
establish systems to track and monitor the prescribing and dispensing of particular prescription
drugs” (Blumenschein et al., 2010). California was the first state to establish a prescription drug
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monitoring program in 1939. Over the years, more and more states followed California in
establishing prescription drug monitoring programs (Fishman et al., 2004). According to the
Alliance of States with Prescription Monitoring Programs (2001) and the National Alliance for
Model State Drug Laws (2014) 49 states (all but Missouri) and the District of Columbia have
prescription drug monitoring programs. The Alliance of States with Prescription Monitoring
Programs was formed in 1990 to facilitate “the exchange of information and ideas among state
and federal agencies on prescription monitoring programs” (Alliance of States with Prescription
Monitoring Programs, n.d., 1).
Attempts to monitor prescription drug use and diversion have evolved over time. Early
forms of prescription drug monitoring programs used triplicate or carbon copy prescriptions.
With advances in the technology during the 1990’s, some states began using computers to
collect, track, and transmit monitoring information (Fishman et al. 2004; Todd, 2010). Another
factor leading to the success and growth of state prescription drug monitoring programs was the
Harold Rogers Prescription Drug Monitoring Program which was funded by the federal
government and provided supporting funds to state prescription drug monitoring programs
(Bureau of Justice Assistance, 2007; Fishman et al., 2004; Harold Rogers prescription drug
monitoring program, 2013; Paulozzi, Kilbourne, & Desai, 2011; Todd, 2010).
An additional attempt by the government to support state prescription drug monitoring
programs was made in 2005. In August of 2005, President George W. Bush signed the National
All Schedules Prescription Electronic Reporting (NASPER) Act into law (Manchikanti,
Whitfield, & Pallone, 2005; Paulozzi et al., 2011). This act provided additional federal funding
to state prescription drug monitoring programs. However, it was more than four years after the
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passing of the legislation before any funding became available and the available funds have been
limited (Todd, 2010).
The federal government also attempted to increase regulations regarding the
manufacturing and distribution of medications. The Controlled Substance Act of 1970 allowed
the Drug Enforcement Administration to oversee the manufacturing and distribution of legal
narcotic medications (Catholic University of America, 2009; Fishman et al., 2004; GAO-02-634,
2002). The Drug Enforcement Administration classifies medications into five distinct categories
or schedules depending upon the drug’s acceptable medical use and the drug’s potential for
abuse or dependency (See Appendix A). “Abuse rate is a determinate factor in the scheduling of
the drug” (DEA 2013). For example, Schedule I drugs are considered the “most dangerous” class
of drugs with a “high potential for abuse” and potentially severe psychological and/or physical
dependence. Schedule I medications have very limited medical use. As the drug schedule
changes-- Schedule II, Schedule III, etc., so does the abuse potential-- Schedule V drugs
represents the least potential for abuse (Sharp, 1991; Curtis et al., 2006). Because of the potential
for abuse, opioid analgesics are regulated under federal narcotics and controlled substances laws
(Joranson et al., 2000). According to Drug Enforcement Agency Office of Diversion Control
(2013), 21 oral opioid analgesics are categorized at Schedule II.
State specifications vary widely but information collected and transmitted by the state
drug monitoring programs often include but are not limited to patient name, date of birth,
prescriber’s name, medication, amount, and directions. (GAO-04-524T, 2004; GAO-02-634,
2002, Kasprak, 2003; Paulozzi et al., 2011; Wilsey et al., 2011).
Although there is significant heterogeneity regarding the specifics of how the prescription
drug information is monitored, “states have found that prescription drug monitoring programs
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are among the most effective tools available to identify and prevent drug diversion at the
prescriber, pharmacy, and patient levels” (Alliance of states with prescription monitoring
programs, 1999, 3; Woodworth, 2013). Benefits of prescription drug monitoring programs
identified by Wang and Christo (2009), Curtis et al. (2006), and the United States General
Accounting Office (GAO-02-634, 2002) include reduced time and effort for law enforcement
agencies to investigate diversion and states with prescription drug monitoring programs have
reduced the supply of controlled substances.
Limitations of Prescription Drug Monitoring Programs
Many medical providers and law enforcement agents will agree that drug monitoring
programs are well intended and can be effective at curbing diversion and abuse; unintended
consequences can limit the utility of aforementioned programs. “Despite great efforts and good
intentions, PDMPs are considered by many healthcare providers to have a collateral of negative
impact on other areas of legitimate medical care” (Fishman et al., 2004, p. 311). One major
criticism of prescription drug monitoring programs is the lack of consistency in what information
is collected, by whom, how often, and what is done with the results (Barrett and Watson, 2003;
Blumenschein et al., 2010; Brushwood, 2003; Simeone, Holland, & Simeone Associates Inc.,
2006; Todd, 2010; U.S. Drug Enforcement Administration, 2011; Wang & Christo, 2009).
Manchikanti et al. (2005) identified another important problem with PDMPs was the lack of
communication between state programs.
Limitations of electronic prescription drug monitoring programs. The two biggest
limitations identified were cost (to the patient or the medical practice) and limited technology.
Manchikanti et al. (2005) noted that not all states and medical facilities provide internet access to
PDMP data. Rural health care facilities may also have limited financial and technologic access to
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PDMP data. Electronic PDMPs carry a continuous cost of technology update (GAO-02-634,
2002) and may be seen as an additional burden to medical practices.
A PA can prescribe up to seven days of a Schedule II medication without the patient
seeing the supervising physician. If your supervising physician has seen the patient
before, and the patient is seeking a refill, you may prescribe any amount, but common
sense would indicate no more than 30 days. (Ohio Association of Physician Assistants,
2013, PA Formulary section, para. 14)
It is common that state laws limit the amount of scheduled medications that can be prescribed at
one time (typically a 30 day supply) and that increases the number of doctor visits for patients,
thus increasing costs.
Effects on patient care and access to opioid medications. The influence of drug
monitoring programs can have far reaching implications not only for medical providers but also
for their patients. Brushwood (2003), Fishman et al (2004), GAO-02-634 (2002) and Woodworth
(2013) agree that patients fear having their information tracked and stored and the possibility for
confidentiality breach may lead to an unfair label of “drug seeking or dependency.”
Blumenschein et al. (2010), Fishman et al. (2004), and Manchikanti et al. (2005) found that
PDMPs had adverse effects on provider prescribing that included inappropriate substitution of
nonregulated medications and a decrease in number of prescriptions written. Clark (1991) also
found that providers showed a reduced inclination to provide narcotic prescriptions for chronic
or acute pain.
Impact on perception of regulations and practice modification. According to Fishman
et al. (2004) and Clark (1991) physicians are reluctant to use PDMPs due to fear of being “red
flagged” as an over prescriber. Barrett and Watson (2005), Gilson and Joranson (2001),
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Manchikanti et al. (2005), and Wang and Christo (2009) determined some prescribers felt that
utilization of prescription drug monitoring programs would place scrutiny on their practice with
potential ill effects of investigation, litigation, or reprimand. GAO-02-634 (2002) and
Woodworth (2013) found that physicians were concerned about having their prescribing
decisions and patterns tracked and being investigated without sufficient cause. Due to this fear of
persecution physicians may be hesitant to prescribe certain scheduled medications or may even
inappropriately substitute medications. To combat the fears of harassment of providers, some
states have added statues of use for the PDMPs that ensure only authorized users access the
information and that the information is used for intended purposed only (GAO-02-634, 2002).
Another identified criticism of using OARRS is the burden of running the report (Woodworth,
2013). This specific argument has been counteracted by enactment of Ohio H.B. 93 that allows
medical support staff the ability to run an OARRS report (Ohio Revised Code 4729.80 (A)(5)
H.B. 93).
Fass and Hardigan (2011) surveyed pharmacists in Florida and results showed that a
majority of the pharmacists felt that results from a PDMP report would not discourage them from
dispensing controlled substances and would not invade patient privacy.
Inconsistency of information gathered and utilization. Significant heterogeneity exists
between states regarding what information is gathered and how it is utilized. Programs vary from
state to state in what information is collected, what drugs are monitored, how information is
collected, who has access to the information, and who monitors the program (Barrett & Watson,
2003; Blumenschein et al., 2010; Brushwood, 2003; GAO-02-634, 2002; Simeone et al., 2006;
Todd, 2010; U.S. Drug Enforcement Administration, 2011; Wang & Christo, 2009). States vary
in their use of electronic versus paper prescription monitoring. Comprehensive coverage of all
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drug schedules offers the most effective monitoring program (GAO-02-634, 2002). Twenty-four
states have mandatory PDMP access requirements that necessitate a prescriber must run a system
query on the patient prior to prescribing controlled medications (National Alliance for Model
State Drug Laws, 2014).
Ohio Automated Rx Reporting System
Following success of prescription drug monitoring programs in multiple states as well as
the technology boom in healthcare in the 1990s, the Ohio Automated Rx Reporting System was
established in 2006. The OARRS is operated by the Ohio State Board of Pharmacy. Data are
collected on prescriptions for medications scheduled II-V. The information collected is available
to pharmacists, prescribers registered with OARRS, and law enforcement (Foxhall, 2010;
Woodworth, 2013). OARRS reports contain patient information including patient name, date of
birth, previous controlled prescriptions (includes prescriber, substance, amount, and date
dispensed), pharmacies where the prescriptions were filled and all addresses used by the patient.
Data reported by Alliance of States with Prescription Monitoring Programs (n.d.) showed that in
2008 21,000,000 prescriptions were recorded by the OARRS and patient history was accessed
353,500 times.
The OARRS has developed a set of guidelines (Rule 4731-11-11) that outlines when to
seek access to OARRS prior to prescribing or personally supplying a controlled substance (State
Medical Board of Ohio, 2011). For an OARRS report to meet ethical standards, the provider
running the report must be currently treating the patient (Ohio Academy of Family Physicians,
2012). The guidelines suggest accessing and running an OARRS report: (a) if a patient is
exhibiting signs of drug abuse or diversion; (b) when you have a reason to believe the scheduled
medication treatment will continue for twelve weeks or more; (c) and at least once a year
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thereafter for patients receiving scheduled medications (Ohio Academy of Family Physicians,
2012; Ohio State Medical Association, 2013; State Medical Board of Ohio, 2011). The OARRS
guidelines outline when a report must be run and when a report should be run.
The Ohio Academy of Family Physicians (2012), Ohio State Medical Association (2013),
and State Medical Board of Ohio (2011) agree that running an OARRS report is required by a
medical provider when: (a) a drug screen result is inconsistent with the treatment plan (i.e., illicit
drugs or medications not prescribed are detected in the urine toxicology screen); (b) a patient
refuses to participate in a drug screen; (c) forging or prescription altering occurs; (d) the patient
is suspected of selling prescription drugs; (e) the patient is suspected of stealing or borrowing
prescription drugs; (f) the patient is suspected of receiving drugs from multiple prescribers; (g)
the patient has been arrested; (h) the patient is suspected of drug diversion; (i) or having a family
member, friend, law enforcement officer, or health care professional express concern related to
the patient’s use of illegal or reported drugs.
The Ohio Academy of Family Physicians (2012), Ohio State Medical Association (2013),
and State Medical Board of Ohio (2011) follow OARRS guidelines and suggest running a report
by a medical provider when: (a) a patient has a known history of chemical abuse or dependency;
(b) a patient frequently requests early refills of scheduled medications; (c) a patient appears
impaired or overly sedated during an office visit or exam; (d) a patient frequently loses
prescriptions; (e) a patient requests drugs by specific name, street name, color; (f) or a patient
shows recurring emergency department visits to obtain reported drugs.
OAARS reports are intended to assist providers in improving prescription medication
management for their patients and to be used as a screening tool to prevent abuse, misuse and
diversion of controlled substances (The Columbus Dispatch, 2010; Feldman et al., 2011; GAO-
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04-524T, 2004; Ohio Academy of Family Physicians, 2012). Although there is a general
consensus among medical providers that the best practice model includes standardization of
medical protocols, the fact that the OARRS is underutilized and occasionally viewed as an
elective tool versus a mandatory standard protocol is concerning.
Ohio Revised Code
The Ohio Revised Code is a compilation of statues that is the source for state regulations
for medical providers and prescribers in the State of Ohio. Bills, statutes and policies are
constantly being revised and amended. Most recently, on September 16, 2014, Ohio House Bill
341 was passed. Ohio Revised Code Sec 4730.53. (A)- Sec. 4731.055. (E) of House Bill 341
(2014) states that a prescriber of controlled substances must request and document the results of
an OARRS report prior to prescribing any medications. The report must include the last 12
months. If the provider works in a county that borders another state, a report must be run for the
bordering state if a drug database is available in that state. If prescribing is to continue after
ninety days, then an additional OARRS report must be run and documented at the ninety day
interval.
There are also some exceptions stated in the Ohio Revised Code Sec 4730.53. (A)- Sec.
4731.055. (E) of House Bill 341 (2014): an OARRS report is not required if there is no report
available, the medication is prescribed for less than a seven day period, if the medication is
furnished for cancer treatment, for hospice care, in a nursing home, in a hospital, or for acute
pain treatment after surgery/delivery.
While the above statutes and laws are helpful in providing suggestions and parameters,
there are always limitations and margins of error that are found. There is no specific timeline set
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for controlled substances that are prescribed after surgery. The term “acute” is not defined in a
timeline.
Prescription Drug Monitoring Program Utilization
“To date little research has examined the efficacy and safety of prescription drug
monitoring programs in clinical practice” (Todd, 2010, p. 24). The limited examination of
prescription drug monitoring program utilization has focused on fields that have a high
population of patients who complain of pain and might require opioid analgesics including
emergency medicine, pain management, pharmacy, and psychology.
Patients with painful conditions often seek care at emergency rooms as a first line of
treatment for their pain, possibly due to late hours, frequently changing staff (shift changes of
nurses and physicians create a window for drug diversion), or a sense that the pain requires
urgent attention. Baehren et al. (2010) examined the influence of a state prescription drug
monitoring program results (Ohio Automated Rx Reporting System OARRS) on clinical
management of patients complaining of pain in the emergency department. Baehren and
colleagues found that emergency room physicians reviewing OARRS data prior to prescribing
medications resulted in altered prescribing plans for 41% of cases, with plans for less opioid
medications in 61% and more opioid medications in 39% of cases. Todd (2010) states that the
data found by Baehren et al. do not reveal why the OARRS data changed the prescribing
decisions. Baehren et al. and Todd agree that awareness and utilization of state prescription drug
monitoring programs are useful tools for emergency medicine providers.
“Because pain is subjectively defined, it is difficult to diagnose and treat” (Wang &
Christo, 2009, p. 508). For this reason, providers in the pain management field have been using
state prescription drug monitoring programs for decades (Gilson & Joranson, 2001; Joranson et
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al., 2002; Katz et al., 2008; Manchikanti et al., 2005; Wang & Christo, 2009). Wang and Christo
(2009) found that while states with prescription monitoring programs had lower incidences of
abuse, misuse and diversion, neighboring states without prescription drug monitoring programs
had increased incidences of abuse, misuse and diversion. Feldman et al. (2012) revealed that
although states with prescription drug monitoring programs reduced the number of prescriptions
for controlled substances being written, there was no evidence this was in a positive manner (i.e.,
preventing diversion versus inadequate pain management). These mixed results of study of
prescription drug monitoring programs in the field of pain management warrant additional
investigation into balancing adequate pain management with reduction in abuse, misuse and
diversion.
The research done by Ulbrich et al. (2010) examined factors influencing the enrollment
of a group of pharmacists in Ohio in the OARRS program. Results of the study showed that the
pharmacists that were enrolled in OARRS did so to decrease misuse, abuse and diversion and
those pharmacists who were not enrolled cited a significant time burden to access the OARRS.
Ulbrich and colleagues used his research results to reform and revise continuing education
information for pharmacists about PDMPs.
The work done by Feldman et al. (2012) was designed to determine if attending physician
behavior influenced the behavior of resident physicians. Feldman and colleagues surveyed
attending and resident physicians at one hospital in the State of Ohio for awareness and
utilization of the OARRS and found that 96% of attending physicians and 81% of resident
physicians had awareness of the state prescription monitoring program. Of those with awareness,
79% of attending and only 51% of residents reported utilizing the OARRS.
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According to Feldman et al. (2012) the primary reason cited for utilizing the OARRS was
concern for medication abuse and that information from the OARRS influenced prescribing
habits by decreasing the quantity of medication given, changing the medication given or
increasing the amount given.
Feldman et al. (2012) found that in relation to physician and resident prescribing trends,
68% of physicians and 79% of residents decreased the amount of medication prescribed when
they consulted the OARRS program. This work is important as it shows that supervising
physician behavior can have a direct positive influence on those around them. Since PAs work
with a supervising physician (directly or indirectly) this is a factor that may influence physician
assistant awareness and utilization of state prescription drug monitoring programs. Similarly,
Schneider et al. (2009) found that physicians and other medical providers were more likely to
follow proper hand hygiene practices if those practices were demonstrated by their supervisors.
Another study by Feldman and colleagues (2011) found 84% of physicians surveyed had
awareness of the OARRS and only 58.8% of those physicians utilized the OARRS. Reasons
cited for accessing OARRS included suspicion of diversion (49%), suspicion of abuse (47%),
additional information (3%), and job requirement (17%).
Barrett and Watson (2003) examined physicians in Virginia and their awareness and
utilization of a prescription drug monitoring program and found less than half the physicians
were aware of the program. “Of the identified physicians that were aware of the prescription
drug monitoring program, only 11% reported utilization of the program” (Barrett & Watson,
2003, p. 8).
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Physician Assistants’ Role in Prescription Drug Monitoring Programs
PAs are licensed independent practitioners. Subsequently, they can perform physical
examinations, diagnose and treat illnesses, order and interpret lab tests, perform procedures,
assist in surgery, provide patient education and counseling, and make rounds in hospitals and
nursing homes. PAs work in all medical fields including, but not limited to, family medicine,
internal medicine, obstetrics and gynecology, pediatrics, general surgery, emergency medicine,
psychiatry, and surgical subspecialties. PAs work in all settings including government, private,
urban, rural, non-profit, group practice, solo practice, hospitals, and education.
O’Connor (2009) states “Health professionals who are not physicians often have more
time to guide, support and monitor patients. Better educated patients can make better-informed
decisions about taking prescribed medications and often adhere more closely to treatment
regimens.” O’Connor agrees that PAs increase accessibility, choice, and quality of care for
patients.
Data from Hooker and colleagues’ (2011) study showed overall supply of PAs is likely to
increase by 72% to 127,821 PAs by 2025. This estimate of PA profession growth may lead
policy makers to revise PAs’ prescriptive policy to allow the most cost effective and efficient use
of PAs to bridge the medical care gap. With the potential policy revision, thought needs to be
given to incorporating knowledge and utilization of state prescription drug monitoring programs.
Prescription drug monitoring programs allow for a more educated approach to
prescribing controlled substances. Informed decisions may be made about what controlled
substances a patient has taken, how much, how often, and who is prescribing the medications.
This information enhances the patient compliance. White and Davis (1999, p. 959) found that
“The delegation of prescriptive authority based upon the discretion of the supervising physician
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has proven to be a safe practice. There has been no record of significantly increased liability or
malpractice claims due to PA prescribing.”
Physician Assistant Pharmacologic Education
In the State of Ohio, PAs must qualify for and obtain a certificate to prescribe. To apply
for a certificate to prescribe, the Ohio Board of Medicine requires the following: (a) transcript
verification of a Masters Degree that is clinically relevant to the PA profession; (b) thirty
pharmacology-specific CME hours (accredited by either the American Academy of Physician
Assistants or the Accreditation Council for Continuing Medical Education); (c) fifteen fiscal and
ethical CME hours; and (d) twenty clinical hours (American Academy of Physician Assistants,
2013; Ohio Association of Physician Assistants, 2013; State Medical Board of Ohio, 2013).
PAs are required to collect 100 continuing medical education (CME) credits a year to
maintain a national certification. Ohio law requires that in addition to the 100 hours of CME,
there must be 12 hours of CME specific to pharmacologic updates. This requirement helps to
ensure that once receiving the prescriptive authority from the state, a PA must stay current on
contemporary pharmacologic treatments (American Academy of Physician Assistants, 2013;
Ohio Association of Physician Assistants, 2013; Medical Board of Ohio [Continuing Medical
Education], 2013).
It is discretionary and not mandatory that a PA supervisory plan include guidelines for
checking OARRS. The PA supervisory plan is developed by the PA, the supervising physician
and possibly the employing entity and may include guidelines for the circumstances and degree
of collaboration necessary for checking OARRS or consultation prior to prescribing or
personally providing scheduled medications to a patient (State Medical Board of Ohio, 2011).
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Ohio Governor John Kasich helped spearhead the development of the Governor’s
Cabinet Opiate Action Team (GCOAT) for Prescriber Education. GCOAT created a continuing
education video to provide information to health care professionals regarding the Guidelines for
Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain (State Medical Board of
Ohio; Opiate Action Team, 2013). The Guidelines have been adopted by the Medical Board,
Nursing Board, Pharmacy Board and Dental Board and establish a trigger point for re-assessment
of chronic pain patients receiving opioids at certain levels for 90 days or longer (State Medical
Board of Ohio; Opiate Action Team, 2013). GCOAT helped fund community-based prescription
drug abuse prevention coalitions, promote education of prescribers, and assist with registration of
prescribers with the OARRS program (Governor’s Cabinet Opiate Action Team, 2013). The
United States General Accounting Office (GAO-04-524T, 2004) found some PDMP’s provided
limited educational sources for physicians and the public. Barrett and Watson (2003) agree that
all educational efforts regarding prescription drug monitoring programs must include PAs as well
as other providers and the public.
Summary
A review of the literature indicates that there has been some study of awareness and
utilization of prescription drug monitoring programs in areas such as emergency medicine, pain
management, psychology, and physician utilization. Literature also revealed a severe underutilization of the OARRS program (Woodworth, 2013). In 2010, Foxhall found that only 20% of
prescribers were signed up to use OARRS. The Columbus Dispatch (2010) found similar results
reveling that approximately 13% of Ohio’s licensed providers were registered to use OARRS.
No research has explored awareness and utilization of the Ohio Automated Rx Reporting System
by PAs.
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In light of the mixed results showing both positive and negative effects of state
prescription drug monitoring programs, future studies should evaluate whether the findings
reflect reduction in abuse and diversion or suboptimal pain treatment (Curtis et al., 2006).
The number of PAs who have prescriptive rights is rising, and an increasing number of
states have prescription drug monitoring programs, both factors dictate a need to explore and
understand the awareness and utilization of state prescription drug monitoring programs by PAs.
The mixed results of earlier research on the awareness and utilization of a state prescription
monitoring program and a lack of studies directly related to physician assistants give reasons for
further investigation of the awareness and utilization of the Ohio Automated Rx Reporting
System by physician assistants.
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CHAPTER 3
METHODOLOGY
Procedures
This study utilizes a quantitative approach to explore the following research questions:
(a) Are physician assistants actively licensed to practice in Ohio aware of (enrolled in) the
OARRS program?; (b) Do physician assistants actively licensed to practice in Ohio utilize the
OARRS program?; (c) Do any factors predict enrollment or utilization of the OARRS program
by physician assistants actively licensed to practice in Ohio?; and (d) Do physician assistants
enrolled in OARRS alter their prescribing practices based on results of OARRS reports?
PAs actively licensed to practice in the State of Ohio (N = 2,563) as of February 25,
2014, were contacted to participate in this study. A previously created, validated, and
implemented questionnaire (Appendix D) by Ulbrich et al. (2010) used with permission, was
adapted, and distributed to physician assistants actively licensed to practice in the State of Ohio
as of February 25, 2014. This study was limited and cannot be generalized to all PAs or all state
prescription monitoring programs.
The present author utilized the adapted questionnaire to examine the awareness and
utilization of the Ohio Automated Rx Reporting System by physician assistants. Data included
age, gender, years in practice, primary setting, primary specialty, current enrollment in OARRS,
number of OARRS reports requested in past month, frequency of OARRS access, reason for
requesting OARRS report, medication denied from OARRS results, supervising physician
notified based on OARRS results, importance of OARRS in prescribing decision, reason for
enrolling in OARRS, reason for accessing OARRS, reason if not enrolled in OARRS, education
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about OARRS, knowledge of the OARRS, access to internet, specialty training, and state of
graduate school.
After receipt and tabulation of the data from the PAs actively licensed to practice in the
State of Ohio, the data was statistically analyzed both descriptively and inferentially.
Research partners. The following people committed to assist in this research design:
1) Safdar Khan, M.D. Chief of Orthopaedic Spine Surgery at The Ohio State University
Wexner Medical Center. Dissertation committee member.
2) The primary investigator Timothy Ulbrich (cf. Ulbrich, 2010) was contacted and
permission gained for use of their research questionnaire.
3) Ohio Board of Medicine was contacted to obtain public record list of actively
licensed physician assistants in the State of Ohio and their contact information.
Selection of subjects. Actively licensed PAs in the State of Ohio were asked to
participate in this study. This study was limited to actively licensed PAs due to increased
likelihood of utilization and awareness of OARRS. The Ohio Board of Medicine was contacted
electronically February 25, 2014 (Appendix G) and the number of actively licensed PAs in Ohio
was reported as 2,563. The Ohio Board of Medicine provided a list of those actively licensed
PAs and their electronic contact information for research purposes only.
Of the 2,563 PAs actively licensed in Ohio, only 2,386 had email addresses on file with
the Ohio board of medicine. An email consisting of a cover letter with an electronic link to the
consent form and the questionnaire (Appendix B, C, D respectively) were created and sent
electronically to each PA actively licensed to practice in the State of Ohio as of February 25,
2014.
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Prior to participating in the study, each PA read and marked a box to indicate informed
consent and willingness to participate in the voluntary study. Marking was used instead of a
signature to keep confidentiality at its highest. The informed consent form, which can be found
in Appendix C, is in accordance with the University of New England Human Subject Review
Board for the protection of Human Subjects (Appendix E). The participants consented and then
completed surveys voluntarily and anonymously.
Stakeholders. What follows are a list of potential stakeholders who may be impacted by
the present research.
1) Physician assistants licensed to practice in Ohio: The OARRS is a vital tool to
physician assistants who prescribe scheduled medications in Ohio.
2) Physician assistants in states with prescription drug monitoring programs: Awareness
and utilization trends of prescription drug monitoring programs by physician assistants
are of interest to physician assistants who prescribe scheduled medications in states
with those programs.
3) Employers of physician assistants in states with prescription drug monitoring
programs: Awareness and utilization trends of prescription drug monitoring programs
by physician assistants are of interest to employers of physician assistants who
prescribe scheduled medications as it could affect policy/procedures and may also
reduce diversion and misuse.
4) Patients: Awareness and utilization trends of prescription drug monitoring programs of
physician assistants may increase access to desperately needed scheduled medications
prescribed safely.
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5) Ohio Automated Rx Reporting System: Awareness and utilization trends of the
OARRS by physician assistants are of interest for the shaping of current or future
policy regarding use of the OARRS, physician assistant prescribing rights, and current
or future continuing education seminars and information.
6) Ohio Opiate Action Team: This team can provide data specific to the State of Ohio.
They have established opioid prescribing guidelines for Ohio. The Ohio Opiate Action
Team has access to Ohio providers in different areas, including physicians,
pharmacists, law enforcement, and others. The team can aid in dissemination of
results.
7) State Medical Board of Ohio: The State Board has access to Ohio providers in
different areas such as physicians, pharmacists, law enforcement, and others. They can
aid in dissemination of results.
Biases. The principal investigator was a currently licensed PA in the State of Ohio who
uses the OARRS. The principal investigator treats a high volume of patients with pain
complaints. The 26-question, self-reported survey that was developed by Ulbrich and colleagues
(2010) was used with permission and adapted for physician assistants. (Appendix D, Appendix
E).
Limitations of the study. What follows are potential limitations to the present study.
1) The study was limited to the participating physician assistants actively licensed to
practice in the State of Ohio. Therefore, findings from this study cannot be
generalized to all physician assistants or physician assistants in other states.
2) The study was limited to physician assistants. Therefore this study does not represent
all medical providers in the State of Ohio.

30

3) The completion of the survey was voluntary. Therefore some physician assistants
choose not to complete the questionnaire, thus limiting sample size.
4) The responses were self-reported.
Basic assumptions. The following were the basic assumptions of the design:
(a) The questionnaire respondents’ interpretation of the questions was accurate; (b) The
questionnaire respondents answered in an honest and thoughtful manner; (c) An existing research
tool developed by Ulbrich et al. (2010) was used with permission and adapted for PAs; and (d)
The questionnaire was previously tested for validity by Ulbrich and colleagues.
Instrumentation
The awareness and utilization of the Ohio Automated Rx Reporting System by PAs was
assessed using a twenty-six-question self-reported survey that was developed by Ulbrich et al.
(2010). The questionnaire was used with permission and adapted for PAs (Appendix D). All PAs
actively licensed to practice in the State of Ohio with an email address on file as of February 25,
2014 were contacted electronically and asked to voluntarily participate in this study.
The survey contained questions regarding factors influencing enrollment or nonenrollment, impact of OARRS on daily practice, previous OARRS education received
knowledge of OARRS, and demographics. Skip-logic (a method to direct the respondent to the
next question based on response to the previous question) was used, and those enrolled in
OARRS answered 25 questions and those not enrolled in OARRS answered 17 questions. Both
groups answered a common set of 16 questions (one question regarding enrollment, two
questions regarding OARRS education, three questions regarding knowledge of OARRS, nine
demographic-type questions, and one open-ended question). Non-enrolled PAs answered an
additional question regarding factors influencing non-enrollment and enrolled PAs answered two
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additional questions regarding factors influencing enrollment, two questions on use of OARRS,
and five questions on the impact of OARRS on daily practice. The survey contained three Likert
scale questions (1 = not important at all; 3 = neither; 5 = very important) to assess the primary
objective (factors influencing enrollment and utilization). No part of the survey identified the
respondent.
Pilot Study
A pilot study was conducted using three PAs at a large university-based medical center.
Each participant voluntarily participated. The participants agreed to participate in the pilot study
knowing that their responses were anonymous but that the researcher would be contacting each
of the participants after the survey completion for feedback. The three participants received the
same email that included the cover letter, and link to the consent form and electronic survey. The
survey responses were collected via SurveyMonkey. After all three participants completed the
survey they were contacted for feedback regarding the study. All three participants agreed that
the email was clear and concise and that the research questions were clear. The three participants
found that the language was clear in the twenty-six question survey and easy to access. The
instructions were clear and the survey smoothly transitioned between questions. Without
prompting, all three participants verbalized the importance of the potential outcome of the survey
results. The participants felt that the questions were appropriate and effective for the subject
matter.
Data Collection
This study examined the awareness and utilization of the Ohio Automated Rx Reporting
System by PAs. The researcher utilized an online survey developed and administered via
SurveyMonkey. The survey is a twenty-six question survey used with permission from Timothy
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Ulbrich (cf. Ulbrich et al., 2010) and adapted for PAs. To increase response rate, a modified
Dillman Tailored Design Method (this method encourages using multiple contacts for survey
type research) was used (Dillman, 2009). The first round of email communication containing the
cover letter and electronic survey link was sent November 1, 2014. A follow up email containing
the same letter and electronic survey link was sent December 1, 2014.
Data Analyses
Quantitative analysis. The data from PAs’ responses were downloaded from
SurveyMonkey as a .csv file. Data were converted to numerical—either scaled or ordinal—or
nominal coding to facilitate analysis in SPSS. The data were examined first in relationship to the
hypotheses and then further, if deemed appropriate.
To assess PA awareness of the OARRS program, descriptive statistics were used and
delineated PAs into two categories of enrolled in the OARRS or not enrolled in the OARRS.
To evaluate if PAs utilized the OARRS, the data were further examined using descriptive
statistics to determine if the PAs’ were actively utilizing (had requested at least one OARRS
report in the last twelve months) the OARRS or not.
Potential factors influencing a PA’s decision to enroll in OARRS or not were considered
using several statistical methods. Descriptive statistics from ranking of factors influencing a
decision not to enroll were reviewed. The Wilcoxon Signed-Rank test was used for further
analysis of the reported importance of factors influencing decision to enroll or to not enroll in the
OARRS and compared factors to identify significant differences in influence.
Multinomial logistical regression was used to decide if relationships exist between
demographic information (self-reported specialty, previous OARRS education and the PAs’
decision to enroll in OARRS. A five-way loglinear analysis was performed to determine a

33

hierarchical unsaturated model for the associations among enrollment, specialized training in
pain management, pain management in the daily setting, graduate of Ohio program, and gender.
Finally, ordinal regressions were run to see if there is a relationship between the PAs’ decision to
enroll in OARRS and years of practice or the knowledge of the OARRS and the likelihood that
participants have enrolled.
Potential factors influencing a PA’s decision to use the OARRS or not were considered
using several statistical methods. Descriptive statistics from ranking of factors influencing a
decision to use OARRS were reviewed. The Wilcoxon Signed-Rank test and a logistic regression
were used for analysis of the reported importance of factors influencing the PA’s decision to
utilize the OARRS.
Descriptive statistics were used to determine if a PA altered their prescribing plan based
on OARRS results.
Secondary analysis. A comparison of importance of common factors influencing
enrollment in OARRS was completed using descriptive statistics. Examination of relationships
between the PAs decision to enroll in OARRS or not and preferences for OARRS education
format was evaluated. A Pearson chi-square test for association was conducted between
enrollment status and preference for education about the OARRS. The Mann-Whitney U Test
was used to compare frequency of use of the OARRS to drug schedule most often leading to a
request for an OARRS report, the decision to deny medication based on the report, contacting a
supervising physician based on the finding in a report, and the use of OARRS by the supervising
physician. Continued analysis was done using the Kruskal-Wallis H Test. The self-reported
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frequency of use OARRS by the PA was compared to the self-reported influence of the factors
on the decision to use the OARRS.
SPSS software was used by the researcher. All statistics were set at the .05 level of
significance.
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CHAPTER 4
RESULTS

The purpose of this chapter is to report and discuss the results of the statistical analysis as
they pertain to the hypotheses. The data were acquired through the development, collection, and
analysis of the survey responses. The study investigated the awareness and utilization of the
Ohio Automated Rx Reporting System by physician assistants. This chapter is divided into the
following sections: (1) rate of return; (2) hypotheses testing; (3) secondary analysis; and (4)
summary.
Rate of Return
The twenty-six question, self-reported survey was uploaded to SurveyMonkey and an
electronic link to the survey. Upon reviewing the list of actively licensed PAs provided by the
State of Ohio Medical Board (N = 2,563 as of February, 25, 2014), it was found that 173 PAs did
not provide an email and 43 of the email addresses were duplicates. After removing myself from
the email list and adjusting for the aforementioned changes, on November 1, 2014 a first round
email was sent to 2,346 PAs licensed in the State of Ohio. Of those 2,346 email addresses, 52
emails were returned as undeliverable. Subsequently those unusable email addresses were
removed and 2,294 PAs were sent a second round email reminder on December 1, 2014 that
again contained the electronic survey link. Additionally after the second round, ten emails
returned undeliverable. As of December 13, 2014, 359 PAs responded to the, a response rate of
15.6%. A follow up email was sent to all the PAs’ emails. PAs who had previously responded
were not excluded. Therefore, there is no way to determine if a PA completed the survey more
than once.
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Descriptive statistics. Of the sample respondents (N = 355), 64.54% were female and
35.46% were male and 65.81% of the respondents reported graduating from a PA school in the
State of Ohio. Just over half (53.99%) of the respondents reported they do not practice in a
setting where they assist with pain management on a daily basis. The majority (94.89%) of the
respondents reported they have not completed any specialized training in pain management.
Years of practice as a physician assistant had the following breakdown among
respondents; 32.59% reported practicing from 1–5 years, 24.28% for 6–10 years, 22.68% for 11–
15 years, 8.95% for 16–20 years, 3.51% for 21–25 years, 3.51% for 26–30 years, and 4.47% for
30 or more years.
When asked about primary practice setting, the top three responses were not-for profit
community hospital (33.55%), ambulatory care clinic (22.68%), and for profit hospital (16.29%).
Government agency 1.28%, nursing home/long term care 0.96%, and home care organization
0.00% were the least selected practice settings.
The top four specialties reported by respondents were emergency medicine (37.06%),
family medicine (13.74%), internal medicine (12.14%), and orthopedics (10.54%).
obstetrics/gynecology (1.92%), physiatry (1.60%), and infectious disease (0.32%) were the three
least reported specialties.
Age was not included in the analysis model because it was highly correlated with years of
practice. Access to the internet was also excluded from the analysis model as 99.68% of
respondents reported having access to the internet at work.
Analysis of hypotheses
Hypothesis one. A total of 2,346 of the 2,563 PAs actively licensed to practice in the
state of Ohio were contacted to participate. Three hundred and fifty-nine PAs responded to the
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survey. Of the 355 PAs who responded, 73.80% indicated that they were currently enrolled in
OARRS and 26.20% indicated they were not enrolled in OARRS (it is understood that if a PA is
not enrolled, then they were not using OARRS). For the purpose of this study awareness is equal
to enrollment. With approximately three of four responding PAs reporting enrollment in the
OARRS, null hypothesis number one; physician assistants actively licensed to practice in the
state of Ohio are unaware of the OARRS should be rejected.
Hypothesis two. Of the 327 responses, 82 reported not being enrolled and therefore are
not using the OARRS. Of the 245 PAs reporting enrollment in OARRS, 10 (4.08%) reported no
use in the past month. This means 92 of the 327 PAs (28.13%) indicated not using the OARRS.
Of the 235 PAs reporting use of the OARRS in the last month, 30.92% reported 1 to 5 requests,
20.77% reported 6 to 10 requests, 21.74% reported 11 to 20 requests and 26.57% reported more
than 20 requests for an OARRS report in the past month. Of the enrolled physician assistants
utilizing OARRS, 74.04% reported average use the OARRS as weekly, daily, or for every
controlled substance prescription. Of this same group, 25.96% reported average use the OARRS
as rarely or at most monthly.
Data shows that 71.87% of responding physician assistants actively licensed to practice
in the state of Ohio do utilize the OARRS and of those enrolled in OARRS, 74.04% report an
average use of at least once per week. Based on the data, we must reject null hypothesis number
two; physician assistants actively licensed to practice in the state of Ohio do not utilize the
OARRS.
Hypothesis three. Potential factors influencing a PA’s decision to enroll in OARRS or
not were considered using several statistical methods. Descriptive statistics from ranking of
factors influencing a decision not to enroll were reviewed. The Wilcoxon Signed-Rank test was
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used for further analysis of the reported importance of factors influencing decision to enroll or to
not enroll in the OARRS and compared factors to identify significant differences in influence.
Multinomial logistical regression was used to decide if relationships exist between
demographic information (self-reported specialty, previous OARRS education and the PA’s
decision to enroll in OARRS. A five-way loglinear analysis was performed to determine a
hierarchical unsaturated model for the associations among enrollment, specialized training in
pain management, pain management in the daily setting, graduate of Ohio program, and gender.
Finally, ordinal regressions were run to see if there is a relationship between the PA’s decision to
enroll in OARRS and years of practice or the knowledge of the OARRS and the likelihood that
participants have enrolled.
Respondents not enrolled in OARRS were asked to rate the importance of seven factors
influencing their decision not to enroll. The two the factors with the highest percentage of very
important or somewhat important responses were understanding the law surrounding the OARRS
database (54.88%) and usefulness to their practice (56.79%). The factors with the lowest
percentage of very important or somewhat important responses were availability of internet
access at work (30.49%) and concern with having to confront a patient if there is any suspicion
of doctor shopping or drug abuse (28.05%). The data are summarized in Table 1.
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Table 1
Factors Influencing the PA’s Decision Not to Enroll in the OARRS
Factors

Very
Important or
Somewhat
Important

Awareness of the OARRS

48.78%

Not
Important or
Somewhat
Not
Important
25.61%

Availability of internet access at
work

30.49%

Understanding of the law
surrounding the OARRS

Mean

Standard
Deviation

3.263

1.447

47.56%

2.563

1.457

54.88%

24.39%

3.463

1.449

Concern with confronting
patients

28.05%

52.44%

2.538

1.359

Usefulness to the practice

56.79%

25.93%

3.430

1.456

Time available at work to access
the OARRS

48.78%

23.17%

3.375

1.325

Time available to enroll in the
OARRS

50.00%

20.73%

3.400

1.327

Respondents enrolled in OARRS were asked to rate the importance of seven factors
influencing their decision to enroll. Overall, the highest importance was given to being able to
assist with decreasing drug diversion (93.25%) and usefulness at the practice site (92.83%) or
being able to assist with decreasing doctor shopping (92.38%). The factor that appears to be the
least influential is education received about the OARRS (37.55%). The data are summarized in
Table 2.
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Table 2
Factors Influencing the PA’s Decision to Enroll in the OARRS
Factors

Very
Important or
Somewhat
Important

Education received about
OARRS

37.55%

Not
Important or
Somewhat
Not
Important
43.04%

Recommendation to enroll from
colleague and/or employer

75.53%

Knowledge of the law
surrounding the OARRS
database

Mean

Standard
Deviation

2.839

1.349

13.92%

3.928

1.228

74.68%

8.02%

3.992

1.050

Usefulness at your practice site

92.83%

3.80%

4.525

0.848

Experience or situation at work
using the OARRS

83.12%

5.91%

4.232

1.017

Being able to assist with
decreasing drug diversion

93.25%

1.27%

4.623

0.682

Being able to assist with
decreasing “doctor shopping”

92.83%

2.11%

4.620

0.736

The Wilcoxon Signed-Rank test was used for further analysis of the reported importance
of factors influencing decision not to enroll in the OARRS and compared factors to identify
significant differences in influence. Seven items were rated by not enrolled respondents to
identify factors that that may have influenced their non-enrollment decision. These were (1)
awareness of the OARRS, (2) availability of internet access at work, (3) understanding of the law
surrounding the OARRS, (4) concern with confronting patients, (5) usefulness to the practice, (6)
time available at work to access the OARRS and (7) time available to enroll in the OARRS.
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Education received about the OARRS was significantly less important than all other
choices (each p < 0.001). The ability to assist with decreasing drug diversion was significantly
more influential than education received about the OARRS (Z = -11.51, p < 0.001),
recommendation to enroll from a colleague or employer (Z = -7.27, p<0.001), knowledge of the
associated laws (Z = -7.39, p < 0.001), and experience or situation at work using the OARRS (Z
= -5.71, p < 0.001). Similarly, being able to assist with decreasing “doctor shopping” was
significantly more influential than education received about the OARRS (Z = -11.34, p < 0.001),
recommendation to enroll from a colleague or employer (Z = -7.30, p < 0.001), knowledge of the
associated laws (Z = -7.15, p < 0.001), and experience or situation at work using the OARRS (Z
= -5.82, p < 0.001). Usefulness at the practice site was found to be significantly more influential
than education received about the OARRS (Z = -10.96, p < 0.001), recommendation to enroll
from a colleague or employer (Z = -6.11, p < 0.001), knowledge of the associated laws (Z = 6.15, p < 0.001), and experience or situation at work using the OARRS (Z = -5.03, p < 0.001).
The Wilcoxon Signed-Rank test was used for similar analysis of the reported importance
of factors influencing a decision to enroll in the OARRS and compared factors to identify
significant differences in influence. Seven items were rated by enrolled respondents to identify
factors that that may have influenced enrollment. These were (1) education received about the
OARRS, (2) recommendation to enroll from a colleague or employer, (3) knowledge of the
associated laws, (4) usefulness at the practice site, (5) experience or situation at work using the
OARRS, (6) ability to assist with decreasing drug diversion and (7) being able to assist with
decreasing “doctor shopping.” The three strongest factors in order of greatest influence were (6)
ability to assist with decreasing drug diversion, (7) being able to assist with decreasing “doctor
shopping,” and (4) usefulness at the practice site, respectively.
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Table 3
Factors Influencing Enrollment in the OARRS for PAs Already Enrolled
Factors

Mean

Standard
Deviation

Education received about the OARRS

2.839

1.345

Recommendation to enroll from a colleague or employer

3.928

1.228

Knowledge of the associated laws

3.992

1.050

Usefulness at the practice site

4.525

0.848

Experience or situation at work using the OARRS

4.232

1.017

Ability to assist with decreasing drug diversion

4.632

0.682

Being able to assist with decreasing “doctor shopping”

4.620

0.736

Using the Wilcoxon Signed-Rank test, analysis of the reported importance of factors
influencing decision to enroll in the OARRS compared factors to identify significant differences
in influence. Education received about the OARRS was significantly less important than all other
choices (each p < 0.001). The ability to assist with decreasing drug diversion was significantly
more influential than education received about the OARRS (Z = -11.51, p < 0.001),
recommendation to enroll from a colleague or employer (Z = -7.27, p < 0.001), knowledge of the
associated laws (Z = -7.39, p < 0.001), and experience or situation at work using the OARRS (Z
= -5.71, p < 0.001). Similarly, being able to assist with decreasing “doctor shopping” was
significantly more influential than education received about the OARRS (Z = -11.34, p < 0.001),
recommendation to enroll from a colleague or employer (Z = -7.30, p < 0.001), knowledge of the
associated laws (Z = -7.15, p < 0.001), and experience or situation at work using the OARRS (Z
= -5.82, p < 0.001). Usefulness at the practice site was found to be significantly more influential
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than education received about the OARRS (Z = -10.96, p < 0.001), recommendation to enroll
from a colleague or employer (Z = -6.11, p < 0.001), knowledge of the associated laws (Z = 6.15, p < 0.001), and experience or situation at work using the OARRS (Z = -5.03, p < 0.001).
A multinomial logistical regression was run to examine prior education about the
OARRS and the self-reported specialty. Four specialties, infectious disease (n = 1), pediatrics (n
= 7), physiatry (n = 5), and psychology (n = 7), were removed due to low reporting. The results
suggest that four statistically significant prior education factors may predict enrollment in the
OARRS by PAs. The factors are prior education received through continuing education (CE)—
live or printed (p = .009), workplace education (p = .010), and State Board of Medicine
newsletter (p = .019). None of the self-reported specialties were found to be significant.
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Table 4
Relationship of PAs’ Enrollment to Specialty and Prior Education about the OARRS
Parameter Estimates

Enrollment

Intercept
Specialty:
[1-Anesthesia]
[2-Cardiology]
[3-Emergency
Medicine]
[4-Family Medicine]
[5-General Surgery]
[7-Internal
Medicine]
[8-Neurology]
[9-OB/GYN]
[10-Orthopedics]
Previous Education:
[None]
[Lectures/college]
[CE-live/printed]
[Workplace educ.]
[Supervising Phys.]
[State Bd. of Med.
Newsletter]
[Article/journal or
magazine]
Note. * p< .05

95% Confidence
Interval for
Exp(B)
Std.
Lower Upper
B
Wald df Sig. Exp(B)
Error
Bound Bound
-3.563 1.759 4.104 1 .043

-1.528
2.280

1.401 1.189 1
1.394 2.674 1

-.742

.932

.634 1

.426

.476

.077

3.381
150.26
9
2.956

-.198
-.174
.337

.981
1.036
.965

.041 1
.028 1
.122 1

.840
.866
.727

.820
.840
1.401

.120
.110
.211

5.609
6.396
9.287

.274
.217
-.432

1.169
1.294
.992

.055 1
.028 1
.190 1

.814
.867
.663

1.316
1.242
.649

.133
.098
.093

12.997
15.677
4.537

.125
-.405
1.482
1.073
.476
1.089

.513
.653
.571
.414
.426
.465

1 .808
1 .535
1 .009*
1 .010*
1 .263
1 .019*

1.133
.667
4.402
2.923
1.610
2.971

.415
.185
1.438
1.298
.699
1.195

3.095
2.399
13.476
6.580
3.710
7.391

-.086

.822

.917

.183

4.592

.059
.385
6.742
6.709
1.252
5.487

.011 1
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.275
.102

.217
9.776

.014
.636

.916

A five-way loglinear analysis was performed to determine a hierarchical unsaturated model to
compare associations between enrollment, specialized training in pain management, pain
management in the daily setting, graduate of an Ohio PA program, and gender. A hierarchical
loglinear analysis was used for secondary review. There were 307 participants who responded.
This produced a model that included all main effects and two two-way associations of enrollment
with specialized training, enrollment with pain management in the setting, enrollment with Ohio
PA program, and enrollment with gender. The model had a likelihood ratio of χ2(2) =3.805, p =
.956. Two statistically significant relationships appear, between enrollment and pain
management training and Ohio PA program (p = .041), and enrollment with Ohio PA program (p
= .023).
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Table 5
Associations Between PA Enrollment in OARRS, Specialized Pain Management Training, Pain
Management in Setting, Ohio Program Graduate, and Gender
Effect
df Partial Chi- Sig.
Square
Enrollment-Pain Mgt. Training-Daily Pain Mgt.-Ohio PA
1
.000
1.000
Program
Enrollment-Pain Mgt. Training-Daily Pain Mgt.-Gender
1
.000
.998
Enrollment-Pain Mgt. Training-Ohio PA Program-Gender
1
.360
.548
Enrollment-Daily Pain Mgt.-Ohio PA Program-Gender
1
.497
.481
Pain Mgt. Training-Daily Pain Mgt.-Ohio PA Program1
.001
.979
Gender
Enrollment-Pain Mgt. Training-Daily Pain Mgt.
1
1.584
.208
Enrollment-Pain Mgt. Training-Ohio PA Program
1
4.185
.041*
Enrollment-Daily Pain Mgt.-Ohio PA Program
1
1.418
.234
Pain Mgt. Training-Daily Pain Mgt.-Ohio PA Program
1
.208
.649
Enrollment-Pain Mgt. Training-Gender
1
1.364
.243
Enrollment-Daily Pain Mgt.-Gender
1
1.523
.217
Pain Mgt. Training-Daily Pain Mgt.-Gender
1
2.004
.157
Enrollment-Ohio PA Program-Gender
1
1.836
.175
Pain Mgt. Training-Ohio PA Program-Gender
1
2.439
.118
Daily Pain Mgt.-Ohio PA Program-Gender
1
.708
.400
Enrollment-Pain Mgt. Training
1
1.844
.174
Enrollment-Daily Pain Mgt.
1
.045
.832
Pain Mgt. Training-Daily Pain Mgt.
1
.039
.844
Enrollment-Ohio PA Program
1
5.191
.023*
Pain Mgt. Training-Ohio PA Program
1
.179
.672
Daily Pain Mgt.-Ohio PA Program
1
.299
.585
Enrollment-Gender
1
.026
.872
Pain Mgt. Training-Gender
1
.148
.700
Daily Pain Mgt.-Gender
1
.501
.479
Ohio PA Program-Gender
1
.727
.394
Enrollment
1
77.599
.000*
Pain Mgt. Training
1
299.905
.000*
Daily Pain Mgt.
1
1.725
.189
Ohio PA Program
1
31.180
.000*
Gender
1
24.996
.000*
Note. * p< .05
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The results of an ordinal regression suggest that no statistically significant relationship exists
between the PA’s decision to enroll in OARRS and years of practice.
Table 6
Relationship of PA’s Decision to Enroll in OARRS and Years of Practice
Variables in the Equation
B
S.E.
Wald
df
-.019
.016
1.491
1

Yrs of
Step 1a Practice
Constant
1.256
.199
a. Variable(s) entered on step 1: Q20.
Note. * p< .05

39.767

p
Exp(B)
.222
.981

1

.000*

3.512

A second binary logistic regression was performed to ascertain the effect knowledge of
the OARRS on the likelihood that participants have enrolled. The logistic regression model was
statistically significant, χ2(1) = 16.236, p < .0005. The level of knowledge about the OARRS
may be a predictor of enrollment.

Table 7
The Effect of Knowledge of the OARRS on the Likelihood of Enrollment
Variables in the Equation
B
S.E.
Wald
Knowledge
.347
.090 14.751
Step 1a
Constant
-1.471
.660
4.963
a. Variable(s) entered on step 1: Knowledge.
Note. * p< .05

df
1
1

p
Exp(B)
.000*
1.415
.026*
.230

From this analysis, one may conclude that prior education through continuing education (CE)live/printed, workplace education, the State Board of Medicine Newsletter, receiving specialized
pain management training, being a graduate of an Ohio PA program, and level of knowledge
about the OARRS may be factors predicting enrollment in the OARRS.
Based on the data, we must reject null hypothesis number three; no factors are predictive of
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awareness of OARRS by physician assistants actively licensed to practice in the state of Ohio.
Hypothesis four. Potential factors influencing a PA’s decision to utilize OARRS were
considered using several statistical methods. Descriptive statistics from ranking of factors
influencing a decision to use OARRS were reviewed. The Wilcoxon Signed-Rank test and a
logistic regression were used for analysis of the reported importance of factors influencing the
PA’s decision to utilize the OARRS.
Respondents enrolled in OARRS were asked to rate the importance of seven factors
influencing their decision to utilize the database. These were (1) availability of internet access at
the workplace, (2) knowledge of the laws surrounding the OARRS database, (3) concern with
having to confront a patient if there is suspicion of doctor shopping or drug abuse, (4)
prescribing behaviors of providers in local area, (5) usefulness to practice site, (6) time available
at work to access an OARRS report, and (7) previous interactions with a patient. Descriptive
statistics indicate the greatest percentage of very important or somewhat important influences
were identified as usefulness at the practice site (91.14%) and availability of internet access at
the workplace (88.19%). The factor that appears to be the least influential was prescribing
behaviors in your local area (41.95%). Looking only at the PAs who are enrolled in the OARRS
but utilizing the database (n = 8), the most influential factor (very important or somewhat
important) was identified as knowledge of the OARRS database (100%) and the least influential
was previous interactions with a patient (37.5%). The data are summarized in Table 8.
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Table 8
Factors Influencing the PA’s Decision to Utilize the OARRS

Availability of internet access at
the workplace

88.19%

Not
Important or
Somewhat
Not
Important
8.02%

Knowledge of the laws
surrounding the OARRS
database

72.88%

10.17%

3.890

1.180

Concern with having to confront
a patient if there is suspicion of
doctor shopping or drug abuse

62.45%

30.385

3.532

1.550

Prescribing behaviors of
providers in local area

41.95%

30.15%

3.123

1.374

Usefulness to practice site

91.14%

2.53%

4.443

0.777

Time available at work to access
an OARRS report

70.89%

14.77%

3.781

1.212

Previous interactions with a
patient

76.69%

13.14%

3.919

1.223

Factors

Very
Important or
Somewhat
Important

Mean

Standard
Deviation

4.414

1.003

The Wilcoxon Signed-Rank Test was used for further analysis of the medians of the
reported importance of factors influencing the PA’s decision to utilize the OARRS and compared
the seven factors to identify significant differences in influence.
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Table 9
Comparison of Medians for Rating of Influences for PA’s Decision to Use OARRS

Internet
access at
work

Knowledge
of
OARRS
laws

Patient
confrontation

Prescribing
behaviors

Z=-6.018
p=.000*

Z=-7.008
p=.000*

Z=-9.127
p=.000*

Z=.204
p=.838

Z=-6.596
p=.000*

Z=-4.847
p=.000*

Z=-3.057
p=.002*

Z=-6.431
p=.000*

Z=6.008
p=.000*

Z=-1.054
p=.292

Z=.546
p=.585

Z=-3.089
p=.002*

Z=7.631
p=.000*

Z=2.379
p=.017*

Z=3.673
p=.000*

Z=10.099
p=.000*

Z=5.535
p=.000*

Z=6.932
p=.000*

Z= -7.212
p=.000*

Z= -6.260
p=.000*

Knowledge
of OARRS
laws

Patient
confrontati
on
Prescribing
behaviors

Value to
practice

Time
available
to access
Note. * p< .05

Value to
practice

Time
available
to access

Previous
patient
interaction

Z=1.450
p=.147
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The results of the Wilcoxon Signed-Rank Test allow us to compare median difference of
factors influencing the decision to use OARRS. The ranking of the factors from most influential
to the least for the decisions to use the OARRS are: usefulness to practice site, availability of
internet access at the workplace, previous interactions with a patient, knowledge of the laws
surrounding the OARRS database, time available to access a report, concern with confronting a
patient, and prescribing behaviors of local providers.
A logistic regression was used to examine the relationships between use and non-use by
enrolled PAs and the seven influences. From this, the only factor with statistical significance is
usefulness to the practice (p = .013). However, knowledge of the laws surrounding the OARRS
database (p = .070) may be of interest.
From this analysis, one may conclude that usefulness to practice site and availability of
internet access at the workplace may be factors predicting use of the OARRS. Based on the data,
we must reject null hypothesis number four; no factors are predictive of utilization of OARRS by
physician assistants actively licensed to practice in the state of Ohio.
Hypothesis five. Descriptive statistics were used initially to determine if results from an
OARRS report would alter the prescriptive plan of the PA. For this analysis, the responses were
confined to those who are both enrolled and utilizing the OARRS. Schedule II or Schedule III
drugs were identified by 94.45% of these respondents as most often leading them to request an
OARRS report. Table 10 shows what schedule of medication most often prompted an enrolled
PA to request an OARRS report.
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Table 10
Drug Types Most Likely Leading to Request of OARRS Report
Drug Schedule

Number

Percentages

Schedule II

159

67.95%

Schedule III

62

26.50%

Schedule IV

11

4.70%

Schedule V

2

0.85%

No Response

2

0.85%

Note. Only PAs enrolled in OARRS responded.
Responses also indicate 90.25% of these PAs have denied prescribing medications to a
patient based on an OARRS report and 83.47% responded that they have contacted a supervising
physician based on the findings on an OARRS report.
The PAs enrolled in and utilizing OARRS were asked about the importance of the
OARRS report in the decision process when precribing controlled medications. Figure 1
illistrates the preceived importance of running an OARRS report when precribing controlled
medications.
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Figure 1. The importance of OARRS report when prescribing controlled substances. It is
important to note that only PAs enrolled in OARRS responded.
In summary, 84.47% of the utilizing PAs consider the OARRS report very important or
somewhat important to the decision process when dispensing a prescription for controlled
substances, 90.25% indicate they have denied prescribing medications to a patient based on an
OARRS report, and 83.47% responded that they have contacted a supervising physician based on
the findings on an OARRS report. From this analysis, one may conclude that the majority of
enrolled and utilizing PAs have altered their prescribing plans based on the findings of an
OARRS report. Based on the aforementioned data, we must reject null hypothesis number five;
physician assistants actively licensed to practice in the state of Ohio do not alter their prescribing
plans as a result of utilization of OARRS.
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Secondary Analysis
Following examination of the five hypotheses, secondary analysis was undertaken. The
purpose is to explore data in a manner that might not be directly supportive of the hypotheses. A
closer look at two questions asked of both enrolled and non-enrolled users was of interest. Each
rated the importance of common factors influencing enrollment or non-enrollment in OARRS.
Descriptive statistics highlight notable differences in importance of these two common factors
influencing a PA’s decision to enroll in OARRS or not; knowledge of laws about OARRS use
and usefulness of OARRS to the PA’s practice. Table 11 shows the results. This difference could
be further explored in future research.
Table 11
Comparison of Importance of Common Factors Influencing Enrollment in OARRS

Median
Mean
SD
Very important or
somewhat important
Not important or
somewhat not important

Knowledge of
Laws
Not
Enrolled Enrolled
n=82
n=237
4
4
3.451
3.992
1.467
1.050

Usefulness to
Practice
Not
Enrolled Enrolled
n=81
n=237
4
5
3.407
4.525
1.447
0.848

54.88%

74.68%

56.79%

92.83%

24.39%

8.02%

25.93%

3.80%
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Using descriptive statistics, a comparison of preferences for OARRS education by
enrolled and non-enrolled PAs was explored. Figure 2 illustrates the findings.

Figure 2. Preference for types of education about OARRS.
A Pearson chi-square test for association was conducted between enrollment status and
preference for education about the OARRS (see Table 12). All expected cell frequencies were
greater than five. There was a statistically significant association between enrollment and
preference for each of three different types of education: law continuing education about the
OARRS, χ2(1)= 5.285, p=.022, Phi (φ)= .127, live general continuing education, 5.623, p=.032,
Phi (φ)= .119 and mailed brochure, χ2(1)= 12.204, p<.001, Phi (φ)= -.193.
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Table 12
Association between Enrollment Status and Preferences for Education about the OARRS
Type of Education about OARRS
Law CE
Live General CE
Workplace Education
Printed CE
Mailed Brochure
State Board of Medicine Newsletter
Article in Journal or Magazine
Note. * p< .05

Chi Square
χ2(1)= 5.285
χ2(1)= 5.623
χ2(1)= 1.268
χ2(1)= 1.606
χ2(1)= 12.204
χ2(1)= .297
χ2(1)= .060

Sig.
p=.022*
p=.032*
p=.260
p=.205
p=.000*
p=.586
p=.806

Phi (φ)= .127
Phi (φ)= .119

Phi (φ)= -.193

The Mann-Whitney U Test (see Table 13.) was used to compare frequency of use of the
OARRS to drug schedule most often leading to a request for an OARRS report, the decision to
deny medication based on the report, contacting a supervising physician based on the finding in a
report, and the use of OARRS by the supervising physician. The drug schedule most often
leading to a request for an OARRS report (p=.068) does not show a statistically significant
difference with frequency of use so this may suggest a significance between frequency of use
and drug schedule most often leading to a request for an OARRS report. A statistically
significant difference was found between the decision to deny medication based on the report
(p=.000), contacting a supervising physician based on the finding in a report (.005), and the use
of OARRS by the supervising physician (.002). A conclusion might be made that these three
factors are not related to frequency of use.
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Table 13
Frequency of OARRS Use and the Rating of Factors on the PA’s Decision to Use OARRS
Null Hypothesis: The distribution of Frequency of Use is the Same Across
Categories of Factors

Sig.

Drug schedule most often leading to a request for an OARRS report

.068

Decision to deny medication based on the report

.000*

Contacting a supervising physician based on the finding in a report

.005*

Use of OARRS by the supervising physician
.002*
Note. * p< .05, Asymptotic significances are displayed. The significance level is .05.
Continued analysis was done using the Kruskal-Wallis H Test (see Table 14). The selfreported frequency of use OARRS by the PA was compared to the self-reported influence of the
factors on the decision to use the OARRS. The knowledge of the laws surrounding the OARRS
database (p = .340), prescribing behaviors of providers in the local area (p = .574), and time
available at work to access and OARRS report (p = .707) were not statistically different from
frequency of use. A conclusion might be made that these factors have statistically significant
relationships to frequency of use.
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Table 14
Frequency of OARRS Use and the Rating of Influences on the PA’s Decision to Use OARRS
Null Hypothesis: The distribution of Frequency of Use of OARRS is the Same
Across Categories of Influences
Availability of internet access at the workplace
Knowledge of the laws surrounding the OARRS database
Concern with confronting a patient about suspected abuse or misuse
Prescribing behaviors of providers in local area
Usefulness to practice site

Sig.
.002*
.340
.000*
.574
.000*

Time available at work to access an OARRS report

.707

Previous interactions with a patient
.020*
Note. * p< .05, Asymptotic significances are displayed. The significance level is .05.
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CHAPTER 5
DISCUSSION
The primary purpose of this study was to examine the awareness and utilization of the
Ohio Automated Rx Reporting System by physician assistants. The literature surrounding
awareness of PDMPs and their use by medical providers is vague. Previous literature revealed a
severe under-utilization of the OARRS program (Woodworth, 2013). In 2010, Foxhall found that
only 20% of prescribers were signed up to use OARRS. The Columbus Dispatch (2010) found
similar results reveling that approximately 13% of Ohio’s licensed providers were registered to
use OARRS. No research had explored awareness and utilization of the Ohio Automated Rx
Reporting System by PAs.
With the number of PAs who have prescriptive rights rising, and mixed results of earlier
research on the awareness and utilization of state PDMPs clear need for further investigation of
the awareness and utilization of the Ohio Automated Rx Reporting System by physician
assistants was identified.
All five null hypotheses were rejected (1) Physician assistants actively licensed to
practice in the state of Ohio are unaware of the OARRS (2) Physician assistants actively licensed
to practice in the state of Ohio do not utilize the OARRS (3) No factors are predictive of
awareness of OARRS by physician assistants actively licensed to practice in the state of Ohio (4)
No factors are predictive of utilization of OARRS by Physician assistants actively licensed to
practice in the state of Ohio and (5) Physician assistants actively licensed to practice in the state
of Ohio do not alter their prescribing plans as a result of utilization of OARRS).
Results indicated that 73.80% of Ohio PAs were currently enrolled in OARRS and
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26.20% were not enrolled in OARRS. Data also showed that 71.87% of responding physician
assistants actively licensed to practice in the state of Ohio do utilize the OARRS and of those
enrolled in OARRS, 74.04% report an average use of at least once per week.
From this analysis, one may conclude that desire to decrease drug abuse/misuse, prior
education through continuing education (CE)-live/printed, workplace education, the State Board
of Medicine Newsletter, receiving specialized pain management training and being a graduate of
an Ohio PA program, being a graduate of an Ohio PA program, and level of knowledge about the
OARRS may be factors predicting enrollment in the OARRS. Years of practice, and selfreported specialties were not significant predictors of a PAs decision to enroll in OARRS. The
two the factors with the highest percentage in influencing a PAs decision not to enroll were
understanding the law surrounding the OARRS database (54.88%) and usefulness to their
practice (56.79%).
From this analysis, one may surmise that OARRS usefulness to practice site and
availability of internet access at the workplace may be factors predicting use of the OARRS.
Based on the data, we must reject null hypothesis number four; no factors are predictive of
utilization of OARRS by physician assistants actively licensed to practice in the state of Ohio.
Results indicate that 84.47% of the utilizing PAs consider the OARRS report very
important or somewhat important to the decision process when dispensing a prescription for
controlled substances, and 90.25% indicate they have altered their prescribing plan and denied
prescribing medications to a patient based on an OARRS report.
Ohio House Bill 341 was passed in September 16, 2014 (Ohio Revised Code Sec
4730.53. (A)- Sec. 4731.055. (E) of House Bill 341, 2014) stating that a prescriber of controlled
substances must request and document the results of an OARRS report prior to prescribing any
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medications. The aforementioned bill, combined with the results of this study, indicate a need to
pursue further research in the area of utilization and awareness of the OARRS by PAs.
Implications of the Limitations on Present and Future Research
Limitations to this research were identified. First, a response rate of 15.6%, although
respectable for survey-type research, may limit the external validity of the results. Secondly, the
accuracy of the email addresses provided by the State of Ohio Medical Board and the potential
for the email to be routed to a “junk mail” box did not allow for an accurate assessment of the
number of PAs receiving the survey. Therefore the response rate reported most likely
underestimated the actual response rate. Third, the responses to the questions were self-reported
and responses to questions about practice setting may be interpreted differently amongst the
respondents. And lastly, although conclusions may be hypothesized to other states with
prescription drug monitoring programs, the findings of this research were based on physician
assistants in Ohio and the Ohio prescription drug monitoring program (OARRS).
Recommendations
Practical application of results. In conclusion, initial efforts should be directed toward
increasing PA awareness and enrollment in the OARRS. Specifically, education should be
continued or developed focusing on law continuing education about the OARRS, providing live
general continuing education, and utilizing a mailed brochure. This, in combination with CME
focused on who should enroll in OARRS, how to use OARRS, when to use OARRS, and
potential benefits of OARRS may enhance the safe and appropriate delivery of commonly
abused and misused controlled medications.

62

Future research. Implications with respect to the results of this study warrant the
following future research and policy recommendations:
1. Future studies utilizing a replication of the present study should be pursued by
obtaining information from other states that utilize a prescription drug monitoring
program.
2. Future studies utilizing a replication of the present study should be pursued by
obtaining information from all providers who utilize the Ohio Automated Rx
Reporting system.
3. Future studies utilizing a replication of the present study should be pursued and
further delineate the notable difference in importance of common factors influencing
a PA’s decision to enroll in OARRS or not.
4. In light of the mixed results showing both positive and negative effects of state
PDMPs, future studies should evaluate whether PDMPS create reduction in abuse and
diversion or suboptimal pain treatment (Curtis et al., 2006).
5. The list of PAs kept by the State Board of Medicine should be updated more
regularly to contact PAs to inquire if they are still practicing in Ohio and current
contact information.
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APPENDIX A
DEA SCHEDULE OF MEDICATIONS

DEA
Schedule

I

Abuse
Potential

Highest

II

High

III

Medium

IV

Low

Example Drugs

Effects

Heroin, (LSD), Marijuana

Unpredictable
effects, severe
psychological or
physical
dependence, death

Methylphenidate,
May lead to severe
morphine, methadone, PCP,
psychological or
codeine, cocaine, Demerol, physical dependence
oxycodone
May lead to
Anabolic steroids, Tylenol
moderate physical
with codeine, Ketamine
dependence or high
psychological
dependence
Diazepam, clonazapam,
midazolam

May lead to limited
psychological or
physical dependence

Cough preparations
May lead to limited
containing codeine:
psychological or
Robitussin AC, Phenergan physical dependence
with Codeine
(Drug Enforcement Agency: Office of Diversion Control, 2013).
V

Lowest
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Medical
Use
No
accepted
use

Accepted
use with
restrictions

Accepted
use

Accepted
use

Accepted
use

APPENDIX B
SURVEY COVER LETTER

November 1, 2014
Dear physician assistant:
I would like to request your participation in a doctoral study examining awareness and utilization
of the Ohio Automated Rx Reporting System (OARRS) by physician assistants. While your
participation is voluntary and anonymous, know that your participation has the potential to
greatly impact the PA profession.
This survey is open to physician assistants actively licensed to practice in the State of Ohio.
Physician assistants are being asked to complete a non-invasive twenty-six-question survey
focused on use of the OARRS. Data will be beneficial to physician assistants within the state of
Ohio, physician assistants in other states with prescription monitoring programs, as well as other
medical providers in states with prescription drug monitoring programs.
My major advisor and committee discussed and approved this project. My study received
approval from the University of New England Institutional Review Board March 4, 2014.
Please use the link below to complete the electronic survey and consent form by November 15,
2014. If you have any questions or concerns, please contact me at (304) 559-7034 or
jrose9@une.edu. Your participation is greatly appreciated. Thank you for your time and effort.
Survey: https://www.SurveyMonkey.com/s/OARRS
Sincerely,
Julia Rose, MSPAS, Principal Investigator
PA-C at The Ohio State University Medical Center
Doctoral Candidate University of New England
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APPENDIX C
CONSENT FORM

Title: Awareness and utilization of the Ohio Automated Rx Reporting System by physician
assistants.
Principle Investigator: Julia Rose
Advisor: Michelle Collay, Ph.D.
Department: Education
Address: University of New England
11 Hills Beach Road
Biddeford, Maine 04005
WRITTEN CONSENT TO ACT AS A RESEARCH SUBJECT
After reading the statement below, please indicate your consent by marking an X in the box on
the consent in the survey.
Statement of Procedure:
This study is a research project conducted for completion of doctoral candidacy
for the University of New England. The purpose of this study is to examine the awareness
and utilization of the Ohio Automated Rx Reporting System by physician assistants. Julia
Rose, a physician assistant at Ohio State University Medical Center and Doctoral
Candidate at the University of New England, is conducting the study.
For this study, participants will be asked to complete and return a survey
consisting of twenty-six questions: age, gender, years in practice, primary setting,
primary specialty, current enrollment in OARRS, number of OARRS reports requested in
past month, frequency of OARRS access, reason for requesting OARRS report,
medication denied from OARRS results, supervising physician notified based on OARRS
results, importance of OARRS in prescribing decision, reason for enrolling in OARRS,
reason for accessing OARRS, reason if not enrolled in OARRS, education about
OARRS, knowledge of the OARRS, access to internet, specialty training, and state of
graduate school.
All personal information will be kept confidential and voluntary. Participants who
would like to obtain the results of this study may request them. If at any time during the
study you need help, or have additional questions you can contact the investigator Julia
Rose- jrose9@une.edu.
I certify that I have read and understand the statement of procedure and agree to participate as a
subject in the research described above. My participation is given voluntary and without being
influenced. I understand that I may discontinue at any time without penalty or prejudice. I certify
that I am at least 18 years of age. Your anonymous consent will be obtained on the first page of
the survey.
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If you have questions about your rights as a research participant, please contact Olgun Guvench,
M.D. Ph.D., Chair of the UNE Institutional Review Board for the Protection of Human Subjects
at (207) 221-4171 or by email at irb@une.edu.
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APPENDIX D
QUALIFICATION SURVEY

Physician assistants actively licensed to practice in the State of Ohio
Please answer the following questions to the best of your ability:
Section I: Questions Regarding the Ohio Automated Rx Reporting System (OARRS)
1. Are you currently enrolled in the Ohio Automated Rx Reporting System (OARRS)?
Yes
No (please skip to section IV)


2. How many patients have you requested an OARRS report for in the past month?
0
1-5
6-10
10-20
>20





3. On average, how often do you access the OARRS database?







For every controlled substance prescription
Daily
Weekly
Monthly
Rarely (less than once per month)
Never

Section II: Impact of the OARRS on Daily Practice
4. Since the start of the OARRS in 2006, which of the following has most often led you to
request an OARRS report?
Schedule II Schedule III Schedule IV Schedule V




5. Have you ever denied medication(s) to a patient based on information obtained from the
OARRS report?
Yes
No


6. Have you ever contacted a supervising physician based on your findings in an OARRS
report?
Yes
No


7. Does your supervising physician use OARRS?
Yes
No
Unsure
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When dispensing a prescription for controlled substances, how important is the OARRS report in
your decision process?
 Not important at all
 Somewhat not important
 Neither
 Somewhat important
 Very important
Section III: Factors Influencing Enrollment (Already Enrolled)
8. How important were the following in your decision to enroll in the OARRS (1=not
important at all; 3=neither; 5 = very important)?
___ Education received about the OARRS (lectures, CE, printed materials, etc).
___ Recommendation to enroll from a colleague and/or employer.
___ Knowledge of the law surrounding the OARRS database.
___ Usefulness at your practice site.
___ Experience or situation at work using the OARRS.
___ Being able to assist with decreasing drug diversion.
___ Being able to assist with decreasing “doctor shopping.”
9. How important are the following in determining whether or not you access an OARRS
report (1=not important at all; 3 = neither; 5 = very important,)? Please skip to question
11 after completing your answer.
___ Availability of internet access at the workplace.
___ Knowledge of the law surrounding the OARRS database.
___ Concern with having to confront a patient if there is any suspicion of doctor
shopping or drug abuse.
___ Prescribing behaviors of providers in your local area.
___ Usefulness to your practice site.
___ Time available at work to access an OARRS report.
___ Previous interactions with a patient.
Section IV: Factors Influencing Enrollment in the OARRS (Not Enrolled)
10. How important are the following in your decision not to enroll in the OARRS (1 = not
important at all, 5 = very important, 3 = neither)?
___ Awareness of the Ohio Automated Rx Reporting System (OARRS).
___ Availability of internet access at work.
___ Understanding of the law surrounding the OARRS database.
___ Concern with confronting a patient regarding a prescription if there is any
suspicion of doctor shopping and/or abuse.
___ Usefulness to your practice site.
___ Time available at work to access an OARRS report.
___ Time available to enroll in the OARRS.
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Section V: OARRS Education
11. What type of education have you received regarding the OARRS?
 None
 Lectures or education during college
 Continuing Education (CE) – live or printed
 Workplace education
 Supervising physician
 State Board of Medicine newsletter
 Article in a journal/magazine
 Other (please specify)_________________________________________
12. Which of the following types of education would you most likely participate in to learn
more about the OARRS? Please check all that apply.
 Law Continuing Education (CE)
 Live General Continuing Education (CE)
 Workplace education
 Printed Continuing Education (CE)
 Mailed brochure
 State Board of Medicine newsletter
 Article in a journal/magazine
Section VI: Knowledge of the Ohio Automated Rx Reporting System (OARRS)
13. Which of the following medications are included in the OARRS database? Please check
all that apply.
 Schedule II
 Schedule III
 Schedule IV
 Schedule V
14. Which of the following groups have access to an OARRS report? Please check all that
apply.
 Pharmacists
 Physician Assistants
 Physicians
 Law enforcement
 Patients
15. Physician Assistants enrolled to receive an OARRS report cannot distribute a copy of the
report to the physician or patient.
True
False
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Section VII: Practice/Education Information
16. What is your specialty? (select one)
 Anesthesia
 Cardiology
 Family Medicine
 Infectious Disease
 Neurology
 Orthopedics
 Physiatry
 Psychology
 Obstetrics/Gynecology
 Other

 Emergency Medicine
 Internal Medicine
 Pediatrics
 General Surgery

17. What is your current primary practice setting? (select one)
 Ambulatory care clinic
 College or university
 Community (not for profit) hospital
 For-profit hospital
 Government agency
 Government hospital
 Home care organization
 Integrated health system
 Nursing home, skilled care, sub-acute or long-term care facility
 Primary care clinic
 University hospital
 Other, please specify__________________________________________
18. Do you have access to the internet at your primary site of practice?
Yes No


19. How many years have you been practicing as a physician assistant?
1-5
6-10
11-15
16-20
21-25
26-30







>30


20. Have you completed any specialized training (e.g. residency, certificate programs, etc) in
pain management?
Yes No


21. Do you practice in a setting where you assist with pain management on a daily basis?
Yes No


22. Did you graduate from a physician assistant school in the state of Ohio?
Yes No


Section VIII: Demographics
23. What is your age?
<30
30-39



40-49
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50-59


>59


24. What is your gender?
Male
Female


25. Please leave any additional comments you have regarding the OARRS database.
___________________________________________________________________
___________________________________________________________________

If there are any questions please feel free to contact me at the following number:
Julia Rose
304-559-7034 (Cell)
Adopted from:
Ulbrich, T. R., Dula, C. A., Green, C. G., Porter, K., & Bennett, M. S. (2010). Factors
influencing community pharmacists' enrollment in a state prescription monitoring
program. Journal of the American Pharmacists Association, 50, 5.
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APPENDIX E
PERMISSION TO USE SURVEY INSTRUMENT
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APPENDIX F
LETTER OF APPROVAL FROM INTERNAL REVIEW BOARD
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APPENDIX G
EMAIL LETTER: OHIO BOARD OF MEDICINE

February 25, 2014

Dear Patrick Randall:
Thank you so much for your assistance on the phone this morning. My name is Julia Rose. I am
a physician assistant at OSU medical center. I am also a doctoral candidate at the
University of New England.
I propose to conduct a survey of physician assistants actively licensed to practice in the State of
Ohio. The data collected will be in based upon the awareness and utilization of the Ohio
Automated Rx Reporting System by physician assistants. Physician assistants are being
asked to complete a non-invasive twenty-six-question survey. Data will be beneficial to
physician assistants within the state of Ohio, physician assistants in other states with
prescription monitoring programs, as well as other medical providers in states with
prescription drug monitoring programs.
I met with my major advisor previously to discuss this project.
I would appreciate your assistance with obtaining the list of active physician assistants in the
State of Ohio and their contact information.
Number of active physician assistants in the State of Ohio: 2,563.
My mail address is 7782 Lerner Drive, Blacklick, OH 43004.
My email is julia.rose@osumc.edu or jrose9@une.edu
If you have any questions or concerns, please contact me at (304) 559-7034. Thank you so much
for your time and effort.
Sincerely,

Julia Rose, MSPAS, Principal Investigator
PA-C at The Ohio State University Medical Center
Doctoral Candidate University of New England
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